The largest purchase of all time was on 2021-06-16 and amounted to 17842 shares of Sage Therapeutics, Inc. for $999,983.
The largest sale of all time was on 2016-05-16 and amounted to 850000 shares of Sage Therapeutics, Inc. for $26.56M.
No biography is available at this moment.
| 2021-06-16 | Sage Therapeutics, Inc. SAGE | director | 17,842 0.0311% | $56.05 | $999,983 | -24.87% | ||
| 2019-02-12 | Sale | Sage Therapeutics, Inc. SAGE | director | 0 – | $0 | $0 | +3.19% | |
| 2018-04-18 | Sale | Sage Therapeutics, Inc. SAGE | director | 48,000 0.1006% | $168.28 | $8.08M | -13.8% | |
| 2018-04-17 | Sale | Sage Therapeutics, Inc. SAGE | director | 70,000 0.1508% | $169.25 | $11.85M | -11.95% | |
| 2017-04-12 | Sale | CytomX Therapeutics, Inc. CTMX | 10 percent owner | 56,714 0.158% | $16.36 | $927,586 | +23.75% | |
| 2016-12-19 | Sale | Blueprint Medicines Corporation BPMC | 10 percent owner | 212,978 0.7487% | $28.19 | $6M | +64.08% | |
| 2016-09-06 | Sale | Editas Medicine, Inc. EDIT | 10 percent owner | 11,780 0.0329% | $15.90 | $187,331 | +8.83% | |
| 2016-05-16 | Sale | Sage Therapeutics, Inc. SAGE | 850,000 2.5266% | $31.25 | $26.56M | +43.28% | ||
| 2015-11-12 | Sale | Alnylam Pharmaceuticals, Inc. ALNY | director | 75,000 0.0894% | $100.14 | $7.51M | -31.72% | |
| 2015-11-11 | Sale | Alnylam Pharmaceuticals, Inc. ALNY | director | 75,000 0.0912% | $107.65 | $8.07M | -35.21% | |
| 2015-09-24 | Sale | Larimar Therapeutics, Inc. LRMR | director | 273,158 1.105% | $43.90 | $11.99M | -83.88% | |
| 2014-09-25 | Sale | Alnylam Pharmaceuticals, Inc. ALNY | director | 90,000 0.1172% | $77.11 | $6.94M | +34.73% | |
| 2014-09-24 | Sale | Alnylam Pharmaceuticals, Inc. ALNY | director | 90,000 0.1179% | $79.08 | $7.12M | +32.14% | |
| 2013-03-26 | Sale | Alnylam Pharmaceuticals, Inc. ALNY | director | 52,000 0.0879% | $23.41 | $1.22M | +135.11% | |
| 2013-03-25 | Sale | Alnylam Pharmaceuticals, Inc. ALNY | director | 53,262 0.0468% | $12.26 | $652,856 | +133.24% |